Collegium Pharma (COLL) Tops Q2 EPS by $1.43

Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.79, $1.43 better than the analyst estimate of $0.36. Revenue for the quarter came in at $82.9 million versus the consensus estimate of $84.77 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Dell shares surge on record AI server bookings
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says